智通财经APP讯，迈威生物(688062.SH)公告，公司收到国家药品监督管理局(NMPA)签发的《受理通知书》，注射用7MW4911的临床试验申请已获正式受理;此外，公司收到美国食品药品监督管理局(FDA)出具的 IND Acknowledgement Letter，确认已收到公司就注射用7MW4911递交的IND申请。
公告显示，7MW4911是基于公司自主知识产权的IDDC™抗体偶联技术平台开发的靶向钙黏蛋白17(CDH17)的创新抗体偶联药物(ADC)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.